2. Amyotrophic lateral sclerosis Clinical trials / Disease details

Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05281484 (ClinicalTrials.gov)	August 31, 2022	7/3/2022	Intermediate Expanded Access Protocol (EAP) CNMAu8.EAP02	A Second Intermediate Expanded Access Protocol for Amyotrophic Lateral Sclerosis With CNM-Au8	Amyotrophic Lateral Sclerosis	Drug: CNM-Au8	Clene Nanomedicine	NULL	Available	18 Years	N/A	All			United States
2	NCT05299658 (ClinicalTrials.gov)	November 13, 2021	8/3/2022	An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS	An Open-Label Extension for the Phase 2, Randomised, Double-Blind, Placebo-Controlled Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS	Amyotrophic Lateral Sclerosis	Drug: CNMAu8	Clene Nanomedicine	NULL	Active, not recruiting	30 Years	80 Years	All	40	Phase 2	Australia